Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2023 Redeem voucher

open access

Vol 70, No 6 (2019)
Review paper
Submitted: 2019-07-22
Accepted: 2019-07-29
Published online: 2019-12-20
View PDF Download PDF file
Get Citation

Endocrine diseases as causes of secondary hyperlipidemia

Łukasz Bułdak1, Bogdan Marek2, Dariusz Kajdaniuk2, Agata Urbanek3, Szymon Janyga3, Aleksandra Bołdys1, Marcin Basiak1, Mateusz Maligłówka1, Bogusław Okopień1
DOI: 10.5603/EP.a2019.0041
·
Pubmed: 31891414
·
Endokrynol Pol 2019;70(6):511-519.
Affiliations
  1. Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland
  2. Department of Pathophysiology and Endocrinology, Medical University of Silesia, Zabrze, Poland
  3. Department of Endocrinology and Diabetology, Regional Specialist Hospital, Rybnik, Poland

open access

Vol 70, No 6 (2019)
Reviews — Postgraduate Education
Submitted: 2019-07-22
Accepted: 2019-07-29
Published online: 2019-12-20

Abstract

Cardiovascular diseases are among the leading causes of increased morbidity and mortality in developed and developing countries. One of the most important risk factors responsible for atherosclerosis and subsequent cardiovascular diseases is hyperlipidaemia. Currently, hyperlipidaemias are divided into several clinical entities. The greatest risk is associated with hypercholesterolaemia. As a result, modern guidelines for the treatment and prevention of atherosclerosis focus predominantly on the reduction of LDL-cholesterol. Hypertriglyceridaemia and atherogenic dyslipidaemia, which are responsible for a less significant increase in the cardiovascular risk, are nowadays secondary targets of the treatment.

During the work-up for hyperlipidaemia one of the essential actions is the exclusion of secondary causes of the lipid abnormalities. Those include, among others, endocrine diseases, diabetes, drugs, nephrotic syndrome, and pregnancy. Data regarding the impact of endocrine disease and diabetes on the lipid profile are scattered. In this review, the authors aimed to perform a thorough analysis of the available publications regarding the topic and the preparation of a comprehensive review dealing with the incidence, clinical features, and the therapy of hyperlipidaemias in patients with endocrine disease. 

Abstract

Cardiovascular diseases are among the leading causes of increased morbidity and mortality in developed and developing countries. One of the most important risk factors responsible for atherosclerosis and subsequent cardiovascular diseases is hyperlipidaemia. Currently, hyperlipidaemias are divided into several clinical entities. The greatest risk is associated with hypercholesterolaemia. As a result, modern guidelines for the treatment and prevention of atherosclerosis focus predominantly on the reduction of LDL-cholesterol. Hypertriglyceridaemia and atherogenic dyslipidaemia, which are responsible for a less significant increase in the cardiovascular risk, are nowadays secondary targets of the treatment.

During the work-up for hyperlipidaemia one of the essential actions is the exclusion of secondary causes of the lipid abnormalities. Those include, among others, endocrine diseases, diabetes, drugs, nephrotic syndrome, and pregnancy. Data regarding the impact of endocrine disease and diabetes on the lipid profile are scattered. In this review, the authors aimed to perform a thorough analysis of the available publications regarding the topic and the preparation of a comprehensive review dealing with the incidence, clinical features, and the therapy of hyperlipidaemias in patients with endocrine disease. 

Full Text:

View PDF Download PDF file
Get Citation

Keywords

hypercholesterolaemia; hypertriglyceridaemia; hyperlipidaemia; endocrine disease; diabetes

About this article
Title

Endocrine diseases as causes of secondary hyperlipidemia

Journal

Endokrynologia Polska

Issue

Vol 70, No 6 (2019)

Article type

Review paper

Pages

511-519

Published online

2019-12-20

Page views

5066

Article views/downloads

4010

DOI

10.5603/EP.a2019.0041

Pubmed

31891414

Bibliographic record

Endokrynol Pol 2019;70(6):511-519.

Keywords

hypercholesterolaemia
hypertriglyceridaemia
hyperlipidaemia
endocrine disease
diabetes

Authors

Łukasz Bułdak
Bogdan Marek
Dariusz Kajdaniuk
Agata Urbanek
Szymon Janyga
Aleksandra Bołdys
Marcin Basiak
Mateusz Maligłówka
Bogusław Okopień

References (76)
  1. Catapano AL, Graham I, De Backer G, et al. ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016; 37(39): 2999–3058.
    CrossRefPubMed
  2. Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol. 2012; 110(6): 823–825.
    CrossRefPubMed
  3. O'Keefe JH, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004; 43(11): 2142–2146.
    CrossRefPubMed
  4. Carr RA, Rejowski BJ, Cote GA, et al. Systematic review of hypertriglyceridemia-induced acute pancreatitis: A more virulent etiology? Pancreatology. 2016; 16(4): 469–476.
    CrossRefPubMed
  5. Fredrickson DS, LEES RS. A system for phenotyping hyperlipoproteinemia. Circulation. 1965; 31: 321–327.
    CrossRefPubMed
  6. Hirano T. Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb. 2018; 25(9): 771–782.
    CrossRefPubMed
  7. Nigam PK. Serum Lipid Profile: Fasting or Non-fasting? Indian J Clin Biochem. 2011; 26(1): 96–97.
    CrossRefPubMed
  8. Pearce EN. Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab. 2012; 97(2): 326–333.
    CrossRefPubMed
  9. Asvold BO, Vatten LJ, Nilsen TIL, et al. The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Eur J Endocrinol. 2007; 156(2): 181–186.
    CrossRefPubMed
  10. Cojić M, Cvejanov-Kezunović L. Subclinical Hypothyroidism — Whether and When To Start Treatment? Open Access Maced J Med Sci. 2017; 5(7): 1042–1046.
    CrossRefPubMed
  11. Ineck BA, Ng TMH. Effects of subclinical hypothyroidism and its treatment on serum lipids. Ann Pharmacother. 2003; 37(5): 725–730.
    CrossRefPubMed
  12. Tokinaga K, Oeda T, Suzuki Y, et al. HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism. Endocr J. 2006; 53(3): 401–405.
    CrossRefPubMed
  13. Andrikoula M, Avades T. Hypolipidaemia is not always indicating liver dysfunction. A review of primary and secondary high density lipoprotein and low density lipoprotein deficiencies. Minerva Med. 2006; 97(6): 487–494.
    PubMed
  14. Patti AM, Giglio RV, Papanas N, et al. Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol. 2019; 12(2): 129–143.
    CrossRefPubMed
  15. Feher M, Greener M, Munro N. Persistent hypertriglyceridemia in statin-treated patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2013; 6: 11–15.
    CrossRefPubMed
  16. Pang J, Chan DC, Watts GF. Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World J Diabetes. 2014; 5(2): 165–175.
    CrossRefPubMed
  17. Katakami N. Mechanism of Development of Atherosclerosis and Cardiovascular Disease in Diabetes Mellitus. J Atheroscler Thromb. 2018; 25(1): 27–39.
    CrossRefPubMed
  18. Okopień B, Buldak L, Bołdys A. Fibrates in the management of atherogenic dyslipidemia. Expert Rev Cardiovasc Ther. 2017; 15(12): 913–921.
    CrossRefPubMed
  19. Lichtenstein AH, Ausman LM, Jalbert SM, et al. Efficacy of a Therapeutic Lifestyle Change/Step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. J Lipid Res. 2002; 43(2): 264–273.
    PubMed
  20. Miller M, Stone NJ, Ballantyne C, et al. American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011; 123(20): 2292–2333.
    CrossRefPubMed
  21. Greenman Y. Management of dyslipidemia in Cushing's syndrome. Neuroendocrinology. 2010; 92 Suppl 1: 91–95.
    CrossRefPubMed
  22. Lopez D, Luque-Fernandez MA, Steele A, et al. "Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study. Ann Intern Med. 2016; 165(8): 533–542.
    CrossRefPubMed
  23. Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002; 87(11): 4872–4878.
    CrossRefPubMed
  24. Anagnostis P, Athyros VG, Tziomalos K, et al. Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009; 94(8): 2692–2701.
    CrossRefPubMed
  25. Meikle AW, Findling J, Kushnir MM, et al. Pseudo-Cushing syndrome caused by fenofibrate interference with urinary cortisol assayed by high-performance liquid chromatography. J Clin Endocrinol Metab. 2003; 88(8): 3521–3524.
    CrossRefPubMed
  26. Perić B, Kruljac I, Šundalić S, et al. Obesity and hypercholesterolemia in patients with prolactinomas: Could DHEA-S and growth hormone be the missing link? Endocr Res. 2016; 41(3): 200–206.
    CrossRefPubMed
  27. Ling C, Svensson L, Odén B, et al. Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab. 2003; 88(4): 1804–1808.
    CrossRefPubMed
  28. Krysiak R, Marek B, Okopień B. Cardiometabolic risk factors in young women with macroprolactinaemia. Endokrynol Pol. 2019; 70(4): 336–341.
    CrossRefPubMed
  29. Berinder K, Nyström T, Höybye C, et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011; 14(3): 199–207.
    CrossRefPubMed
  30. Krysiak R, Szkróbka W, Okopień B. Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia. Pharmacol Rep. 2019; 71(1): 61–66.
    CrossRefPubMed
  31. Woodmansee WW, Gordon MB, Molitch ME, et al. Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis. Endocrine. 2018; 61(1): 105–117.
    CrossRefPubMed
  32. Tsuchiya H, Onishi T, Mogami H, et al. Lipid metabolism in acromegalic patients before and after selective pituitary adenomectomy. Endocrinol Jpn. 1990; 37(6): 797–807.
    CrossRefPubMed
  33. Ioaniţiu D, Bartoc R, Ispas I, et al. The dyslipemic syndrome in acromegaly. Endocrinologie. 1982; 20(1): 25–36.
    PubMed
  34. Nikkilä EA, Pelkonen R. Serum lipids in acromegaly. Metabolism. 1975; 24(7): 829–838.
    CrossRefPubMed
  35. Takeda R, Tatami R, Ueda K, et al. Secondary type V hyperlipoproteinemia in an acromegalic patient without overt diabetes. Endokrinologie. 1982; 79(1): 140–148.
    PubMed
  36. Cansu GB, Yılmaz N, Yanıkoğlu A, et al. Assessment of diastolic dysfunction, arterial stiffness, and carotid intima-media thickness in patients with acromegaly. Endocr Pract. 2017; 23(5): 536–545.
    CrossRefPubMed
  37. Golkowski F, Krzentowska-Korek A, Baldys-Waligorska A, et al. Goiter, cardiovascular and metabolic disorders in patients with acromegaly. Endocr Regul. 2011; 45(4): 191–197.
    PubMed
  38. Tsuchiya H, Onishi T, Mogami H, et al. Lipid metabolism in acromegalic patients before and after selective pituitary adenomectomy. Endocrinol Jpn. 1990; 37(6): 797–807.
    CrossRefPubMed
  39. Takeda R, Tatami R, Ueda K, et al. The incidence and pathogenesis of hyperlipidaemia in 16 consecutive acromegalic patients. Acta Endocrinol (Copenh). 1982; 100(3): 358–362.
    CrossRefPubMed
  40. Takeda R, Tatami R, Ueda K, et al. Secondary type V hyperlipoproteinemia in an acromegalic patient without overt diabetes. Endokrinologie. 1982; 79(1): 140–148.
    PubMed
  41. Caron PJ, Petersenn S, Houchard A, et al. PRIMARYS Study Group. Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naïve patients with acromegaly: data from the PRIMARYS study. Clin Endocrinol (Oxf). 2017; 86(4): 541–551.
    CrossRefPubMed
  42. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305(24): 2556–2564.
    CrossRefPubMed
  43. Lewiński A, Smyczyńska J, Stawerska R, et al. National Program of Severe Growth Hormone Deficiency Treatment in Adults and Adolescents after Completion of Growth Promoting Therapy. Endokrynol Pol. 2018; 69(5): 468–524.
    CrossRefPubMed
  44. van der Klaauw AA, Biermasz NR, Feskens EJM, et al. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol. 2007; 156(4): 455–462.
    CrossRefPubMed
  45. Itoh E, Hizuka N, Fukuda I, et al. Metabolic disorders in adult growth hormone deficiency: A study of 110 patients at a single institute in Japan. Endocr J. 2006; 53(4): 539–545.
    CrossRefPubMed
  46. Kohno H, Tanaka T, Fujieda K, et al. Favorable Impacts of Growth Hormone (GH) Replacement Therapy on Atherogenic Risks in Japanese Children with GH Deficiency. Clin Pediatr Endocrinol. 2012; 21(2): 15–20.
    CrossRefPubMed
  47. Shimatsu A, Tai S, Imori M, et al. Efficacy and safety of growth hormone replacement therapy in Japanese adults with growth hormone deficiency: a post-marketing observational study. Endocr J. 2013; 60(10): 1131–1144.
    CrossRefPubMed
  48. Norrman LL, Johannsson G, Sunnerhagen KS, et al. Baseline characteristics and the effects of two years of growth hormone (GH) replacement therapy in adults with GH deficiency previously treated for acromegaly. J Clin Endocrinol Metab. 2008; 93(7): 2531–2538.
    CrossRefPubMed
  49. Claessen KM, Appelman-Dijkstra NM, Pereira AM, et al. Abnormal metabolic phenotype in middle-aged GH-deficient adults despite long-term recombinant human GH replacement. Eur J Endocrinol. 2014; 170(2): 263–272.
    CrossRefPubMed
  50. Andrikoula M, Sertedaki A, Andrikoula S, et al. PROP-1 gene mutations in a 63-year-old woman presenting with osteoporosis and hyperlipidaemia. Hormones (Athens). 2013; 12(1): 128–134.
    CrossRefPubMed
  51. Ishibashi S, Murase T, Yamada N, et al. Hyperlipidaemia in patients with hypopituitarism. Acta Endocrinol (Copenh). 1985; 110(4): 456–460.
    CrossRefPubMed
  52. Dutkowska A, Konieczna A, Breska-Kruszewska J, et al. [Recomendations on non-pharmacological interventions in women with PCOS to reduce body weight and improve metabolic disorders [Zalecenia dotyczące postępowania niefarmakologicznego u kobiet z PCOS celem zmniejszenia masy ciała i poprawy zaburzeń metabolicznych]. Endokrynol Pol. 2019; 70(2): 198–212.
    CrossRefPubMed
  53. Milewicz A, Kudła M, Spaczyński RZ, et al. The polycystic ovary syndrome: a position statement from the Polish Society of Endocrinology, the Polish Society of Gynaecologists and Obstetricians, and the Polish Society of Gynaecological Endocrinology. Endokrynol Pol. 2018; 69(4).
    CrossRefPubMed
  54. Puurunen J, Piltonen T, Puukka K, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013; 98(12): 4798–4807.
    CrossRefPubMed
  55. Wang Q, Würtz P, Auro K, et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. Int J Epidemiol. 2016; 45(5): 1445–1457.
    CrossRefPubMed
  56. Stumpf MA, Kluthcovsky AC, Okamoto JM, et al. Acute pancreatitis secondary to oral contraceptive-induced hypertriglyceridemia: a case report. Gynecol Endocrinol. 2018; 34(11): 930–932.
    CrossRefPubMed
  57. Basaria S. Male hypogonadism. Lancet. 2014; 383(9924): 1250–1263.
    CrossRefPubMed
  58. Dimitriadis GK, Randeva HS, Aftab S, et al. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy. Endocrine. 2018; 60(1): 175–184.
    CrossRefPubMed
  59. Mohler ER, Ellenberg SS, Lewis CE, et al. The Effect of Testosterone on Cardiovascular Biomarkers in the Testosterone Trials. J Clin Endocrinol Metab. 2018; 103(2): 681–688.
    CrossRefPubMed
  60. Zhang J, Yang B, Xiao W, et al. Effects of testosterone supplement treatment in hypogonadal adult males with T2DM: a meta-analysis and systematic review. World J Urol. 2018; 36(8): 1315–1326.
    CrossRefPubMed
  61. Rezanezhad B, Borgquist R, Willenheimer R, et al. Association between serum levels of testosterone and biomarkers of subclinical atherosclerosis. Aging Male. 2018; 21(3): 182–186.
    CrossRefPubMed
  62. Zhang KS, Zhao MJ, An Q, et al. Effects of testosterone supplementation therapy on lipid metabolism in hypogonadal men with T2DM: a meta-analysis of randomized controlled trials. Andrology. 2018; 6(1): 37–46.
    CrossRefPubMed
  63. Dos Santos Mota MP, Gomes Moura IC, Marinho RM, et al. Evaluation of Cardiovascular Risk in Climacteric Women: A Cross-Sectional Study. J Midlife Health. 2018; 9(3): 123–129.
    CrossRefPubMed
  64. Welty F. Preventing clinically evident coronary heart disease in the postmenopausal woman. Menopause. 2004; 11(4): 484–494.
    CrossRefPubMed
  65. Miller VM, Naftolin F, Asthana S, et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019 [Epub ahead of print]; 26(9): 1071–1084.
    CrossRefPubMed
  66. Han D, Trooskin S, Wang X. Prevalence of cardiovascular risk factors in male and female patients with primary hyperparathyroidism. J Endocrinol Invest. 2012; 35(6): 548–552.
    CrossRefPubMed
  67. Lacour B, Roullet JB, Liagre AM, et al. Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am J Kidney Dis. 1986; 8(6): 422–429.
    CrossRefPubMed
  68. Godang K, Lundstam K, Mollerup C, et al. The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism. Endocr Connect. 2018; 7(8): 941–948.
    CrossRefPubMed
  69. Murase T, Yamada N, Ohsawa N, et al. Decline of postheparin plasma lipoprotein lipase in acromegalic patients. Metabolism. 1980; 29(7): 666–672.
    CrossRefPubMed
  70. Werumeus Buning J, Dimova LG, Perton FG, et al. Downregulation of cholesteryl ester transfer protein by glucocorticoids: a randomised study on HDL. Eur J Clin Invest. 2017; 47(7): 494–503.
    CrossRefPubMed
  71. Dullaart RPF, De Vries R, Scheek L, et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest. 2004; 64(3): 205–215.
    CrossRefPubMed
  72. Duvillard L, Florentin E, Lizard G, et al. Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. Diabetes Care. 2003; 26(5): 1540–1544.
    CrossRefPubMed
  73. Arnaldi G, Scandali VM, Trementino L, et al. Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology. 2010; 92(Suppl 1): 86–90.
    CrossRefPubMed
  74. Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol. 2018; 14(5): 259–269.
    CrossRefPubMed
  75. Twickler TB, Cramer MJM, Dallinga-Thie GM, et al. Adult-onset growth hormone deficiency: Relation of postprandial dyslipidemia to premature atherosclerosis. J Clin Endocrinol Metab. 2003; 88(6): 2479–2488.
    CrossRefPubMed
  76. Valdemarsson S, Hansson P, Hedner P, et al. Relations between thyroid function, hepatic and lipoprotein lipase activities, and plasma lipoprotein concentrations. Acta Endocrinol (Copenh). 1983; 104(1): 50–56.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl